These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 30101875

  • 41. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C, Rutkowski P, Brzuszkiewicz K, Bylina E, Limon J, Siedlecki JA.
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [Abstract] [Full Text] [Related]

  • 42. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
    Farag S, van der Kolk LE, van Boven HH, van Akkooi ACJ, Beets GL, Wilmink JW, Steeghs N.
    Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
    Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD.
    Am J Surg Pathol; 2004 Jul; 28(7):889-94. PubMed ID: 15223958
    [Abstract] [Full Text] [Related]

  • 45. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY, Shi YQ, Zhou Y, Fu H, Zhao G.
    J Surg Oncol; 2008 Sep 01; 98(3):175-8. PubMed ID: 18618605
    [Abstract] [Full Text] [Related]

  • 46. Use of tissue microarrays and immunohistochemistry to standardize the diagnosis of gastrointestinal stromal tumors.
    Ogino J, Asanuma H, Sakurai S, Matsuno Y, Miyokawa N, Yamashiro K, Fukazawa Y, Muraoka S, Iwaki Y, Kondo N, Hasegawa T.
    Pathol Int; 2010 Nov 01; 60(11):707-13. PubMed ID: 20946519
    [Abstract] [Full Text] [Related]

  • 47. Synchronous poorly-differentiated neuroendocrine carcinoma and gastrointestinal stromal tumor of the stomach: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA.
    Ding J, Sun P, Cai XY, Fei SH, Wu J, Qi YK, Liu ZB, Yuan L, He YJ, Song H, Chen WX.
    Int J Clin Exp Pathol; 2014 Nov 01; 7(12):9076-80. PubMed ID: 25674291
    [Abstract] [Full Text] [Related]

  • 48. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
    Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J.
    Scand J Gastroenterol; 2006 Jul 01; 41(7):805-11. PubMed ID: 16785193
    [Abstract] [Full Text] [Related]

  • 49. [Gastrointestinal stromal tumors: definition, histological, immunohistochemical, and molecular features, and diagnostic strategy].
    Coindre JM, Emile JF, Monges G, Ranchère-Vince D, Scoazec JY.
    Ann Pathol; 2005 Oct 01; 25(5):358-85; quiz 357. PubMed ID: 16498290
    [Abstract] [Full Text] [Related]

  • 50. Loss of DOG-1 expression associated with shift from spindled to epithelioid morphology in gastric gastrointestinal stromal tumors with KIT and platelet-derived growth factor receptor α mutations.
    Agaimy A, Wang LM, Eck M, Haller F, Chetty R.
    Ann Diagn Pathol; 2013 Apr 01; 17(2):187-91. PubMed ID: 23218903
    [Abstract] [Full Text] [Related]

  • 51. [Application and value of mutation detection in diagnosis and treatment of gastrointestinal stromal tumor].
    Cao H, Wang M.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 01; 16(3):208-11. PubMed ID: 23536336
    [Abstract] [Full Text] [Related]

  • 52. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM.
    Histopathology; 2009 Jul 01; 55(1):53-62. PubMed ID: 19614767
    [Abstract] [Full Text] [Related]

  • 53. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
    Du CY, Shi YQ, Zhou Y, Fu H, Zhao GF.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul 01; 11(4):371-5. PubMed ID: 18636362
    [Abstract] [Full Text] [Related]

  • 54. A KIT-negative, DOG1-positive epithelioid GIST of the stomach harboring a novel PDGFRA exon 14 single nucleotide deletion.
    Rizzardi C, Marzinotto S, Avellini C, Melato M, Mariuzzi L.
    Anticancer Res; 2012 May 01; 32(5):1775-8. PubMed ID: 22593460
    [Abstract] [Full Text] [Related]

  • 55. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP.
    Am J Surg Pathol; 2015 Jul 01; 39(7):922-30. PubMed ID: 25970686
    [Abstract] [Full Text] [Related]

  • 56. Mutational profile of KIT and PDGFRA genes in gastrointestinal stromal tumors in Peruvian samples.
    Buleje J, Acosta Ó, Guevara-Fujita M, Enriquez Y, Taxa L, Machicado E, Lizaraso-Caparó F, Fujita R.
    Rev Esp Enferm Dig; 2015 Feb 01; 107(2):72-8. PubMed ID: 25659388
    [Abstract] [Full Text] [Related]

  • 57. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.
    Clin Cancer Res; 2006 Apr 15; 12(8):2622-7. PubMed ID: 16638875
    [Abstract] [Full Text] [Related]

  • 58. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.
    Cho S, Kitadai Y, Yoshida S, Tanaka S, Yoshihara M, Yoshida K, Chayama K.
    Int J Oncol; 2006 Jun 15; 28(6):1361-7. PubMed ID: 16685437
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.
    Yi ES, Strong CR, Piao Z, Perucho M, Weidner N.
    Appl Immunohistochem Mol Morphol; 2005 Jun 15; 13(2):157-61. PubMed ID: 15894928
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.